Atlas Trials

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Clinical trial NCT07241468 · RECRUITING

Trial details

NCT number
NCT07241468
Sponsor
Changhai Hospital
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Start date
2025-11-15
Primary completion
2026-12-30
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.